Epithalon vs HLDF-6

Epithalon is believed to activate telomerase, the enzyme responsible for maintaining telomere length, with several in vitro and animal studies reporting telomere elongation. It also appears to regulate the expression of p53 and other cell-cycle control genes, modulate the hypothalamic-pituitary axis via pineal gland activity, and upregulate antioxidant defences including superoxide dismutase and catalase.

Epithalon (Ala-Glu-Asp-Gly; AEDG peptide) is a synthetic tetrapeptide developed by Vladimir Khavinson as a more stable analog of the native pineal tetrapeptide epithalamin, proposed to restore physiological circadian rhythm regulation and telomerase activity in aging cells, and to exert broad anti-aging effects through epigenetic gene expression modulation in pineal and other tissues. Epithalon is proposed to activate telomerase and modulate telomere maintenance in aging somatic cells, normalize melatonin production and the neuroendocrine-immune axis, and restore physiological parameters that decline with aging; in vitro studies and preclinical animal models provide mechanistic support for these effects. Published human studies from the Khavinson group include a controlled clinical trial demonstrating epithalon's effects on retinal function in retinitis pigmentosa patients and observational data showing melatonin rhythm normalization in elderly subjects, representing the strongest indexed clinical evidence specifically for epithalon; both studies are formally indexed in PubMed. Epithalon has no FDA approval and no approved indication in any Western jurisdiction; published clinical evidence derives from a single research group without external independent replication by standard Western trial methodology, and while the mechanistic and observational research is indexed in peer-reviewed journals, the evidence base does not meet the threshold for established efficacy in any recognized clinical condition. Epithalon dosage protocols: no human clinical trial has established a standardized dosing regimen for epithalon. The published Khavinson clinical research does not report specific dose-response data in a format translatable to general dosing guidance. No dose-ranging clinical trial has been conducted for epithalon; research community protocols are derived from the animal research and Khavinson group bioregulator framework rather than validated human studies. Intranasal delivery has also been explored due to direct CNS access via the olfactory pathway. Epithalon is a research compound with no approved clinical dosing guidelines in any jurisdiction.

Modulates cholinergic neurotransmission. Reduces amyloid-β toxicity and protects against oxidative stress-induced neuronal damage. May enhance memory consolidation via acetylcholine pathway upregulation.

HLDF-6 (human leukemia differentiation factor hexapeptide; TGENHR) is a synthetic hexapeptide derived from a sequence of the HLDF protein, investigated in preclinical models for neuroprotective properties in conditions including Alzheimer's disease and Parkinson's disease, where it is proposed to reduce neuroinflammation, protect against beta-amyloid toxicity, and attenuate dopaminergic neuron loss. HLDF-6 is proposed to modulate inflammatory cytokines and oxidative stress pathways, with potential effects on acetylcholinesterase activity; preclinical animal studies in transgenic Alzheimer's models and MPTP-induced Parkinson's models suggest cognitive-protective properties at the cellular and behavioral level. No published human clinical trials, pharmacokinetic studies, or safety evaluations of HLDF-6 administration have been indexed in PubMed; the entirety of its evidence base consists of rodent and cell-based studies, and no regulatory authority has evaluated or approved HLDF-6 for any human indication. HLDF-6 has no FDA approval or regulatory approval in any jurisdiction; it is a neuroprotective research compound with a defined mechanistic hypothesis and an exclusively preclinical evidence base, and the translation of its animal model findings to human therapeutic outcomes has not been investigated.